Company Profile
Inscripta
Company Overview
At Inscripta, we're more a calling than a company. Maybe it's our commitment to help feed, fuel and heal humanity. Making the MAD7™ CRISPR nuclease free for research purposes may not be typical in this industry, but it's typical for us. Our primary purpose is to empower scientists whose gene editing research is stifled by current technical and licensing limitations.
We want you to make bigger discoveries, faster and at unprecedented scale, experiencing those bold breakthroughs that the Onyx™ platform will provide. We live up to our press by 'walking the walk' every day, bringing you revolutionary tools that serve the greater good. Because Inscripta's more than a company, it's our calling.
Company History
Maybe it’s our commitment to help feed, fuel and heal humanity.
Making the MAD7™ CRISPR nuclease free for research purposes may not be typical in this industry, but it’s typical for us. Our primary purpose is to empower scientists whose gene editing research is stifled by current technical and licensing limitations.
We want you to make bigger discoveries, faster and at unprecedented scale, experiencing those bold breakthroughs that the Onyx™ platform will provide. We live up to our press by ?‘walking the walk’ every day, bringing you revolutionary tools that serve the greater good. Because Inscripta™ is more than a company, it’s our calling.
-Principles count-
Throughout our own breakthroughs, business management practices and office policies, the principles we value stay the same. Be bold, act responsibly and inspire others.
Our technology incorporates specific biosecurity practices for ethical genome engineering. Contributions that power progress are shared. And every member of our team is valued for their unique perspective and contributions.
As a company, we move forward together inclusively and respectfully. And by our business practices we are promoting society to do the same.
Notable Accomplishments / Recognition
On December 10, 2019 Inscripta, Inc. announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. The new funds will be used to accelerate applications expansion and commercialization of the company’s revolutionary Onyx™ Digital Genome Engineering platform.
The Onyx platform is the world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. The new platform offers immediate and significant benefits that will give scientists in genome discovery, healthcare, bio-industrial materials development and manufacturing, and sustainability the power to design, engineer, evaluate, and track results of genome engineering experiments in their own labs.
“We have been extremely impressed with the Inscripta team’s passion, focus, and relentless execution, which culminated in the successful launch of the Onyx Digital Genome Engineering platform,” said Paul Conley, PhD, Managing Director & Venture Studio Director at Paladin Capital Group. ?“We are thrilled to lead this funding round and believe Inscripta’s technology will be essential for enabling biology to become the driving force of our economy.”
“The overwhelming interest we received with the recent launch of our Onyx platform along with this significant funding offer tremendous validation of our novel approach to genome engineering and its power to unlock the full potential of the emerging bioeconomy,” said Kevin Ness, PhD, CEO of Inscripta. ?“We are excited to see that by overcoming the limitations of existing CRISPR-based gene editing, our digital genome engineering tools are already having a significant impact by enabling researchers to design experiments that were previously impossible. The new funding provides us with the resources to ramp up faster to meet the anticipated high demand for our platform.”
About Inscripta
Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7™ CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, NanoDimension, MLS Capital, JS Capital Management LLC, and Oak HC/FT. For more information, visit www?.inscrip?ta?.com.
Benefits
Inscripta offers a competitive base salary, bonus plan, benefits package and stock options to all team members. Join us and work with a great team of people developing the world's first scalable platform for benchtop Digital Genome Engineering. Inscripta is headquartered in Boulder, CO with offices in Pleasanton and San Diego, CA.